期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 474, 期 2-3, 页码 223-226出版社
ELSEVIER
DOI: 10.1016/S0014-2999(03)02080-6
关键词
pramipexole; vesicular monoamine transporter; Parkinson's disease; vesicle function; eticlopride
资金
- NIDA NIH HHS [DA04222, DA00869, DA1367, DA11389] Funding Source: Medline
Pramipexole is a dopamine D2/D3 receptor agonist used to treat Parkinson's disease. Both human and animal studies suggest that pramipexole may exhibit neuroprotective properties involving dopamine neurons. However, mechanisms underlying its neuroprotective effects remain uncertain. The present results reveal a novel cellular action of this agent. Specifically, pramipexole rapidly increases vesicular dopamine uptake in synaptic vesicles prepared from striata of treated rats. This effect is: (1) associated with a redistribution of vesicular monoamine transporter-2 (VMAT-2) immunoreactivity within nerve terminals; and, (2) prevented by pretreatment with the dopamine D2 receptor antagonist, eticlopride. The implications of this finding relevant to the treatment of neurodegenerative disorders are discussed. (C) 2003 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据